[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100619245":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":29,"centralContacts":33,"locations":41,"responsibleParty":56,"collaborators":25,"id":58,"slug":59,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":25,"eligibilityCriteria":64,"healthyVolunteers":65,"sex":66,"minAge":67,"maxAge":68,"enrollmentInfo":69,"targetDuration":25,"studyType":72,"phases":73,"briefSummary":75,"conditions":76,"keywords":25,"overallStatus":44,"whyStopped":25,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"Genentech, Inc.","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"RO7875913","EXPERIMENTAL","Participants will receive RO7875913.",[13],"Drug: RO7875913",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","Participants will receive Placebo.",[19],"Drug: Placebo",[21,26],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Participants will receive RO7875913 as per the schedule described in the protocol.",[9],null,{"type":22,"name":15,"description":27,"armGroupLabels":28,"otherNames":25},"Participants will receive placebo as per the schedule described in the protocol.",[15],[30],{"name":31,"affiliation":5,"role":32},"Clinical Trials","STUDY_DIRECTOR",[34,39],{"name":35,"role":36,"phone":37,"phoneExt":25,"email":38},"Reference Study ID Number: GO46451 https:\u002F\u002Fforpatients.roche.com\u002F No email attachments.","CONTACT","888-662-6728 (U.S. and Canada)","global-roche-genentech-trials@gene.com",{"name":40,"role":36,"phone":25,"phoneExt":25,"email":25},"Fastest response: use the inquiry form. https:\u002F\u002Fwww.gene.com\u002Fcontact-us\u002Fsubmit-medical-inquiry",[42],{"facility":43,"status":44,"city":45,"state":46,"zip":47,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":25},"New Zealand Clinical Research - Christchurch","RECRUITING","Christchurch","Canterbury","8011","New Zealand","NZ",{"type":51,"coordinates":52},"Point",[53,54],172.63333,-43.53333,{"lat":54,"lon":53},{"type":57,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100619245","phase-1-a-dose-escalation-study-of-ro7875913-in-healthy-participants-100619245",false,"NCT07342114","A Dose-Escalation Study of RO7875913 in Healthy Participants","A Phase I Dose-Escalation Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of RO7875913 in Healthy Volunteers","Inclusion Criteria:\n\n* Agreement to adhere to the contraception requirements\n* Body weight \\> 40 kilogram (kg) with a body mass index of 18-30 kg per meter square (kg\u002Fm\\^2)\n\nExclusion Criteria:\n\n* Positive test result for hepatitis B surface antigen, hepatitis C virus (HCV), or human immunodeficiency virus (HIV) antibody screen\n* History of any malignancy\n* Major surgical procedure within 28 days prior to initiation of study treatment, or anticipation of need for a major surgical procedure during the study\n* History or clinical manifestations of significant metabolic, hepatic, renal, pulmonary, cardiovascular, hematologic, gastrointestinal, urologic, neurologic, or psychiatric disorders\n* Known allergy or hypersensitivity to any component of the RO7875913 formulation\n* Treatment with investigational biologic therapy (or blinded comparator) within 90 days or 5 drug elimination half-lives, whichever is longer, prior to initiation of study drug\n* Treatment with investigational non-biologic therapy (or blinded comparator) within 28 days or 5 drug elimination half-lives, whichever is longer, prior to initiation of study drug\n* Treatment with any immunosuppressive medication within 28 days or 5 drug elimination half-lives, whichever is longer, prior to initiation of study drug",true,"ALL","18 Years","65 Years",{"count":70,"type":71},40,"ESTIMATED","INTERVENTIONAL",[74],"PHASE1","The purpose of this study is to evaluate the safety, pharmacokinetics, and pharmacodynamics of RO7875913 in healthy participants.",[77],"Healthy Volunteers","2026-06-19",{"date":80,"type":81},"2026-06-24","ACTUAL",{"date":83,"type":81},"2026-03-11",{"date":85,"type":71},"2026-12-31",{"name":5,"class":6},1]